Infliximab in patients with inflammatory DMARDs-refractory eye disease

Authors

  • Elmer García-Salazar Unidad Ambulatoria de Reumatología UNAR. Servicio de Reumatología, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú.
  • Henry Terrazas Unidad Ambulatoria de Reumatología UNAR. Servicio de Reumatología, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú.
  • Javier Gonzales Residentes de la especialidad de Reumatología, sede HNERM, Universidad Nacional Mayor de San Marcos.
  • Miguel Fernández Residentes de la especialidad de Reumatología, sede HNERM, Universidad Nacional Mayor de San Marcos.

DOI:

https://doi.org/10.15381/anales.v74i3.2640

Keywords:

Scleritis, infliximab, positive ANCA vasculitis, rheumatoid arthritis.

Abstract

Experience with infliximab (monoclonal antibody with strong anti-inflammatory action) for treatment of ocular inflammatory disease secondary to rheumatic diseases and refractory to disease-modifying antirheumatic drugs (DMARDs) is described. We evaluated the cases of a 50 year-old patient with active rheumatoid arthritis (RA) and a 37 year-old patient with myeloperoxidase antineutrophil cytoplasmic vasculitis antibody (MPO ANCA) without noble organ affectation, both with bilateral scleritis and left eye corneal perforation with iris prolapse. They received infliximab 3-5 mg/kg IV at 0, 2, 6, and 8 weeks. Infliximab was effective and safe for treatment of scleritis associated to RA and MPO ANCA positive vasculitis refractory to treatment with both DMARDs and high dose corticosteroids. Corneoscleral tissue grafts developed favorably with infliximab.

Downloads

Published

2013-09-16

Issue

Vol. 74 No. 3 (2013)

Section

Casos clínicos

License

Copyright (c) 2013 Elmer García-Salazar, Henry Terrazas, Javier Gonzales, Miguel Fernández

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Those authors who have publications with this magazine accept the following terms:

  1. Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
  2. Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
  3. Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).

How to Cite

1.
García-Salazar E, Terrazas H, Gonzales J, Fernández M. Infliximab in patients with inflammatory DMARDs-refractory eye disease. An Fac med [Internet]. 2013 Sep. 16 [cited 2024 Jul. 17];74(3):227-30. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/2640